Clinical trial
Gemcitabine and Capecitabine in Treating Patients With Advanced and/or…
NCT00084942 · Roswell Park Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00084942 |
|---|---|
| Title | Gemcitabine and Capecitabine in Treating Patients With Advanced and/or Inoperable Cholangiocarcinoma or Carcinoma of the Gallbladder |
| Official title | A Phase II Study of Gemcitabine in Combination With Capecitabine in Advanced Cholangiocarcinoma |
| Lead sponsor | Roswell Park Cancer Institute, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Extrahepatic Bile Duct Cancer, Gallbladder Cancer |
| Intervention type | Drug |
| Interventions | capecitabine, gemcitabine hydrochloride |
| Start date | Oct 1, 2002 |
| Primary completion | May 1, 2004 |
| Completion | Nov 1, 2006 |
| First posted | Jun 11, 2004 |
| Last update posted | Jan 12, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: